Innogen Pharmaceutical Soars 296% in Hong Kong Debut Following GLP-1 Diabetes Drug Approval

Guangzhou Innogen Pharmaceutical Group Co delivered a spectacular Hong Kong stock market debut on Friday, with shares surging as much as 296% to HK$74 before settling around 172% higher by 11 am. The performance positions the Chinese diabetes and obesity drugmaker for the best first-day showing among the 54 companies that began trading in Hong Kong this year.

The biotech company raised nearly HK$683 million ($87 million) in its initial public offering at HK$18.68 per share, generating extraordinary investor interest with retail subscriptions reaching HK$370 billion ($47.1 billion) - more than 5,000 times oversubscribed according to local media reports.

First Domestic GLP-1 Breakthrough in China

Innogen's market debut comes on the heels of a significant regulatory milestone. The company's lead product, efsubaglutide alfa (formerly known as Supaglutide, trade name: Einoqing), received approval from China's National Medical Products Administration in January 2025, becoming the first domestically developed humanized long-acting GLP-1 receptor agonist in the country.

The drug belongs to the GLP-1 class of medications that have gained widespread global adoption for treating diabetes and obesity. Innogen commercially launched efsubaglutide alfa for type 2 diabetes treatment in China in February 2025, generating RMB 38.14 million in revenue during the first five months of 2025 - the company's first commercial revenues.

Expanding Beyond Diabetes Treatment

While currently approved only for diabetes in China, efsubaglutide alfa is advancing through final-stage clinical testing for weight loss applications. Chief Executive Officer Qinghua Wang indicated that weight loss data is expected around the end of 2026, citing "significant" progress and preliminary weight loss data from mid-stage clinical trials.

"People have just recently realized the large unmet medical need — and market potential — in chronic metabolic diseases, as lifestyle changes prompt a rise in obesity rates in China," Wang said in a Bloomberg TV interview.

The company is also developing efsubaglutide alfa for metabolic dysfunction-associated steatohepatitis (MASH) indications, alongside five preclinical candidate drugs in its pipeline.

Financial Performance and Market Position

Founded in 2014, the science-driven biopharmaceutical company recorded net losses of RMB 733 million in 2023, RMB 175 million in 2024, and RMB 97.875 million in the first five months of 2025, reflecting typical biotech development costs prior to commercialization.

Despite the strong market reception, Innogen faces intense competition from established pharmaceutical giants Eli Lilly & Co and Novo Nordisk A/S, as well as a growing wave of domestic Chinese companies developing similar GLP-1 products.

International Expansion Plans

The company has outlined plans to expand efsubaglutide alfa's reach beyond China, with applications for licenses in Southeast Asia and Latin America under consideration. This international strategy could significantly expand the addressable market for the company's lead product.

Broader Market Impact

Innogen's successful debut contributed to a broader surge in Hong Kong's innovative pharmaceuticals sector, with related concept stocks rising collectively. The strong performance follows a recent trend of successful biotech IPOs in Hong Kong, including Ab&B Bio-Tech, Nanjing Leads Biolabs, and Duality Biotherapeutics, all of which more than doubled on their first trading days.

China International Capital Corp and Citic Securities Co served as joint sponsors of the offering, while Deutsche Bank AG and Macquarie Capital Ltd acted as coordinators for the IPO.